ATI Inc. (ATI) Q2 2026 earnings review
Massive Guidance Raise as Margins Inflect Upward
ATI delivered an exceptional beat-and-raise quarter, validating its multi-year strategy to pivot heavily into aerospace and defense. Revenue grew 11% YoY to $1.26B, but the real story is profitability: Adjusted EBITDA surged 37% to $284.4M, driving margins up 440 basis points to 22.6%. The company is successfully leveraging capacity constraints to secure favorable pricing while mix-shifting toward high-margin Defense (+36% YoY) and Jet Engine (+14% YoY) markets. Management aggressively hiked full-year guidance, pushing the FY26 EBITDA midpoint up by $125M to $1.16B. While the collapsing Medical segment and recurring 'one-time' adjustment charges warrant a skeptical eye, ATI's core engine is accelerating rapidly.
🐂 Bull Case
The AA&S segment proved it can match HPMC's profitability, rocketing to a 23.7% margin from 14.4% a year ago. Pricing power is structural and translating directly to the bottom line.
Backlog grew 18% YoY to a record $4.4 billion. Defense sales surged 36%, and commercial jet engines grew 14%, providing high-visibility runway through at least 2027.
🐻 Bear Case
The Medical segment collapsed 41% YoY, and Airframes slipped 2%. Growth is entirely dependent on the Jet Engine and Defense verticals.
ATI excluded $23.6M in 'special items' (start-up, transformation, restructuring) this quarter, following $26.4M in Q1. Persistent adjustments obscure true GAAP profitability.
⚖️ Verdict: 🟢
Bullish. The 440 bps jump in EBITDA margin and the massive $125M upward revision to FY26 guidance completely overshadow the weakness in legacy fringe segments.
Key Themes
Defense and Jet Engines Surging
The A&D end markets are Accelerating rapidly. Total Defense sales jumped 36% YoY to $162M, powered by an incredible 90% YoY Defense growth surge within the AA&S segment alone. Commercial Jet Engines followed closely with a 14% increase to $508M. These two pillars are overwhelmingly driving ATI's top-line growth.
AA&S Margin Catch-Up
Profitability is Accelerating across the board, but the AA&S segment was the standout. Segment EBITDA margin exploded to 23.7% (up from 14.4% in 25Q2 and 18.1% in 26Q1). While a $9.9M asset sale gain assisted, management explicitly noted that higher pricing and a richer product mix drove the structural expansion.
Record Backlog Visibility
Backlog remains Stable at structurally elevated levels, reaching a new record of $4.4 billion (up 18% YoY). With lead times extending to two years on proprietary products, ATI is locked into long-term growth and insulated from short-cycle volatility.
Medical Segment Collapse Contradicts Narrative
While management paints a flawless growth picture, the Medical segment is Reversing sharply. Revenue collapsed 41% YoY from $38.9M to just $23.0M. Additionally, Airframes declined 2% YoY to $191.7M, exposing a stark divergence where ATI's non-engine/non-defense verticals are actively shrinking.
Qualification Costs Dragging HPMC
Despite strong top-line sales, HPMC segment EBITDA margins are Decelerating sequentially, slipping from 24.9% in Q1 to 24.1% in Q2. Management attributed this margin drag to higher manufacturing costs specifically tied to qualification requirements for the new Mexico facility and the titanium electron-beam furnace.
Persistent Special Item Adjustments
The cadence of 'one-time' charges remains Stable but uncomfortably elevated. ATI excluded $23.6M in Q2 (start-up, transformation, restructuring, AR sale losses) following $26.4M in similar exclusions in Q1. Investors must question when transformation costs simply become recurring operating expenses.
Macro: Demand Outstrips Supply
ATI is benefiting from a highly favorable macro environment where global A&D material demand significantly outpaces available supply. This structural imbalance provides ATI with immense pricing leverage and the ability to selectively allocate capacity to its highest-margin products.
Other KPIs
Stable. Dropped slightly from 34.8% of annualized sales in Q1 2026. While still slightly above long-term targets, ATI is effectively managing inventory and receivables despite the rapid volume ramp.
Accelerating. Cash provided by operating activities reached $131.8M while capital expenditures consumed $68.6M. The resulting cash generation funded $50M in share repurchases, leaving $495M on the current authorization.
Reversing. Jumped from 11.8% in Q1 back to a normalized level, primarily due to the timing of discrete tax benefits for share-based compensation.
Guidance
Accelerating aggressively. Management raised the midpoint to $1,160M from the prior $1,035M. This implies phenomenal 35% YoY growth over FY25's $859.3M, signaling massive operating leverage converting to cash.
Accelerating sequentially. A $310M midpoint represents a clear step-up from Q2's $284.4M print, demonstrating that momentum is expected to build into the second half of the year.
Accelerating. Pulled up sharply from the prior $4.20 - $4.48 range, tracking directly with the EBITDA expansion and reflecting lower ongoing share counts due to steady buybacks.
Accelerating. Upgraded from the prior $465M-$525M outlook, driven by higher earnings flow-through that is more than covering the capital outlays required for the new titanium and nickel capacity projects.
Key Questions
Medical Segment Viability
The Medical segment collapsed 41% YoY to $23M. What are the structural issues driving this decline, and at what point does it make strategic sense to divest this non-core business?
HPMC Margin Drag Duration
HPMC margins compressed sequentially due to Mexico facility and titanium electron-beam furnace qualification costs. When do you expect these specific facilities to transition from margin drags into margin contributors?
Earnings Quality & Special Items
The company routinely excludes roughly $25M per quarter in 'start-up, transformation, and restructuring' costs from adjusted earnings. When will these transformation efforts be fully completed so GAAP and non-GAAP earnings can converge?